S-Calprotectin (S100A8/S100A9): A Potential Marker of Inflammation in Patients with Psoriatic Arthritis

Table 1

Characteristics of patients and controls.

	Control; group 1, 𝑁=31	Mono-/oligoarthritis; group 2, 𝑁=32	Polyarthritis; group 3, 𝑁=33	𝑃 value
Mean age, years, mean (±SD)	52.5 (±15)	50.9 (±12.7)	50.0 (±15.7)	ns
Gender (female/male)	15/16	17/15	15/18	ns
Duration of skin disease, years, mean (±SD)	—	24.9 (±13.3)	22.7 (±16.0)	ns
Duration of joint disease, years, mean (±SD)	—	16.4 (±15.5)	15.2 (±10.8)	ns
ESR, mm/h, mean (±SEM)	—	10.2 (±1.25)	18.5 (±2.1)	0.002
hs-CRP, mg/L, mean (±SEM)	1.6 (±0.37)	3.17 (±0.58)	6.5 (±1.07)	0.026^1; 0.012^2; 0.000^3
S-calprotectin ng/mL, mean (±SEM)	308.85 (±20.82)	705.05 (±85.5)	1471.93 (±403.9)	0.000^1; 0.017^2; 0.000^3

ns: not significant.
1Comparison between group 1 and group 2.
2Comparison between group 2 and group 3.
3Comparison between group 1 and group 3.